3-碘吲唑-6-羧醛 、 2-(4-甲基哌嗪-1-基)吡啶-5-硼酸频那醇酯 以the title compound was obtained as a beige solid (57 mg, 99%)的产率得到3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-6-carbaldehyde
[EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER AVEC CEUX-CI
申请人:UNIV HEALTH NETWORK
公开号:WO2010115279A1
公开(公告)日:2010-10-14
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
申请人:Pauls Heinz W.
公开号:US20110065702A1
公开(公告)日:2011-03-17
The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
申请人:Sampson Peter B.
公开号:US20120149686A1
公开(公告)日:2012-06-14
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof:
Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Kinase inhibitors and method of treating cancer with same
申请人:Sampson Peter Brent
公开号:US08481525B2
公开(公告)日:2013-07-09
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.